

# Amendment Tool

v1.6 06 December 2021

For office use

QC: Yes

## Section 1: Project information

Short project title*:	Toxicity from biologic therapy (BSRBR-RA)			
IRAS project ID* (or REC reference if no IRAS project ID is available):	64202 (minimal dataset) / REC Ref: 00/8/053			
Sponsor amendment reference number*:	Substantial Amendment 31 (SA31)			
Sponsor amendment date* (enter as DD/MM/YY):	30 January 2025			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>This amendment introduces an update to the BSRBR-RA patient recruitment poster (BSRBR-RA Patient Poster v.3.0_13112023).</p> <p>It also introduces a document featuring an illustration of a participant's data journey ('BSRBR-RA Your Data Journey (for print) v1.0_03042024' and 'BSRBR-RA Your Data Journey (for web) v.1.0_03042024'). This document helps to provide clarity to patients regarding what is involved during participation and gives a straightforward and easy to understand overview of how the data provided by participants is used to help improve treatment outcomes for people with Rheumatoid Arthritis (with a link and QR code to access a number of lay summaries based on study data). Both versions of this document contain the same content, they are just formatted slightly differently based on how they are to be used.</p> <p>Both the BSRBR patient recruitment poster and the BSRBR patient data journey documents have been designed to be displayed in the waiting rooms of rheumatology clinics/on the BSRBR website (bsrbr.org)/provided electronically as required.</p>			
Project type (select):	<div>Specific study</div> <div>Research tissue bank</div> <div>Research database</div>			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes	No		
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<div>NHS/HSC REC</div> <div>Ministry of Defence (MoDREC)</div>			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes	No		
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	<div>England</div> <div>Yes</div>	<div>Wales</div> <div>No</div>	<div>Scotland</div> <div>No</div>	<div>Northern Ireland</div> <div>No</div>
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes	No		
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes	No		
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes	No		
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes	No		
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes	No		
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes	No		
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes	No		
Did the study involve children OR does the amendment introduce this?:	Yes	No		
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes	No		
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes	No		
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes

## Section 2: Summary of change(s)

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	<p>This amendment introduces an update to the BSRBR-RA patient recruitment poster (BSRBR-RA Patient Poster v.3.0_13112023). Like the previous version (Version 2: 17/07/2017, approved by the REC/HRA on 24/08/2017 as part of substantial amendment 25), this poster has been designed to be displayed in the waiting rooms of rheumatology clinics and also on the BSRBR website (bsrbr.org)/provided electronically (as required).</p> <p>Brief outline of changes:</p> <ul style="list-style-type: none"><li>• Poster re-worded to be more patient friendly and remove specific references to eligibility criteria, replacing with more general information about the study and its aims, and what participation in the study involves, with an invitation to the patient to consult their rheumatologist at their next clinic appointment to find out more.</li><li>• Graphics updated to make the poster more consistent with the BSRBR-RA website (www.bsrbr.org) and make it more visually appealing to potential participants.</li></ul> <p>Document is provided (for sites who wish to use it) as a recruitment aid and to provide information for potential participants who might not be aware of the study.</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	<p>This amendment introduces a new document featuring an illustration of a participant's data journey ('BSRBR-RA Your Data Journey (for print) v1.0_03042024' and 'BSRBR-RA Your Data Journey (for web) v1.0_03042024'). Both versions of this document contain the same content, they are just formatted slightly differently based on how they are to be used.</p> <p>Document is provided (for sites who wish to use it) for display in the waiting rooms of rheumatology clinics, to give clarity to patients regarding what is involved during participation and gives a straightforward and easy to understand overview of how the data provided by participants is used to help improve treatment outcomes for people with Rheumatoid Arthritis (with a link and QR code to access a number of lay summaries based on study data). It will also be used on the BSRBR-RA website (bsrbr.org) and can be provided electronically by both sites and the study team directly.</p>			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Add another change	

## Section 3: Declaration(s) and lock for submission

**Declaration by the Sponsor or authorised delegate**

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Lynne MacRae
Email address*:	FBMHethics@manchester.ac.uk

**Lock for submission**

**Please note:** This button will only become available when all mandatory (\*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

**Section 4: Review bodies for the amendment**

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																	Category	
	UK wide:						England and Wales:				Scotland:			Northern Ireland:					
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	
Change 1:	N					(Y)				(Y)				(Y)				(Y)	C
Change 2:	Y					Y				Y				Y				Y	C
Overall reviews for the amendment:																			
Full review:	Y					Y				Y				Y				Y	
Notification only:	N					N				N				N				N	
Overall amendment type:	Substantial																		
Overall Category:	C																		